

 Early Warning System

EIB-20220025

MINERVAX (IDFF)



## Quick Facts

<b>Countries</b>	Denmark
<b>Financial Institutions</b>	European Investment Bank (EIB)
<b>Status</b>	Approved
<b>Bank Risk Rating</b>	U
<b>Voting Date</b>	2022-12-13
<b>Borrower</b>	MINERVAX APS
<b>Sectors</b>	Education and Health, Industry and Trade
<b>Investment Type(s)</b>	Loan
<b>Investment Amount (USD)</b>	\$ 53.12 million



---

## Project Description

The loan will finance the research, development and innovation activities of the Danish biotechnology company MinervaX ApS. The project falls under InnovFin Infectious Diseases Finance Facility, part of Horizon 2020, a joint European Commission and EIB initiative. The aim is to support the development of a recombinant protein-based vaccine for pregnant women preventing adverse pregnancy outcomes and life-threatening infections caused by Group B streptococcus.



---

## Investment Description

- European Investment Bank (EIB)



---

### Private Actors Description

Minervax ApS operates as a biotechnology company. The Company develops vaccines against Group B streptococcus (GBS) infections by utilizing a particular fusion protein. Minervax serves patients in Denmark.



---

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	MINERVAX APS	Client	-

---



## Contact Information

*Project contacts not available at the time of disclosure.*

### **Borrower - MinervaX:**

Per Fischer - CEO

Email: [info@minervax.com](mailto:info@minervax.com)

Address: Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark

Website: [www.minervax.com](http://www.minervax.com)

### ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

### ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: [complaints@eib.org](mailto:complaints@eib.org), by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: [http://www.eib.org/attachments/strategies/complaints\\_mechanism\\_policy\\_en.pdf](http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf)

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



---

## Media

- Denmark: EIB supports development of novel maternal vaccine with €50 million loan for Danish life sc